Prescription medicine

Landiolol Brand names: Rapiblyk

Landiolol (Rapiblyk) is a prescription medicine with an FDA approval on record since 2024. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the landiolol FDA label on DailyMed (effective June 19, 2026, AOP Orphan Pharmaceuticals GmbH); the NDA 217202 record on Drugs@FDA; every landiolol label on DailyMed.

Highlights of the record

FDA label of June 19, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia.

Forms and strengths

280 mg

Injection (powder) (lyophilized) for solution.

On the market

Earliest approval on file: November 22, 2024 Rapiblyk, Aop Hlth Us; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Last listed patent: April 25, 2034 Rapiblyk injection; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 81 through July 30, 2026

What is landiolol used for?

From the label: indications and usage
RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia. RAPIBLYK is a beta adrenergic blocker indicated for the short-term reduction of ventricular rate in: adults with supraventricular tachycardia including atrial fibrillation and atrial flutter ( 1 ), and pediatric patients with supraventricular tachycardia.

FDA pharmacologic class: beta-Adrenergic Blocker.

Source: FDA drug label (RAPIBLYK), NDA217202 (Aop Hlth Us), as published by AOP Orphan Pharmaceuticals GmbH, effective June 19, 2026 (SPL set 27e7f20f-78a4-f1a9-e063-6394a90ae465), via openFDA; the full label on DailyMed

Is there a generic for landiolol (Rapiblyk)?

No generic landiolol is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 1 patent for Rapiblyk injection, the last expiring on April 25, 2034. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2024 earliest approval on file
2034 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What does the landiolol label say about other medicines?

The landiolol label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine named	Section	What the label says
Epinephrine	warnings and precautions	Patients using beta-blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions [see Drug Interactions ( 7 )].

Check landiolol against other medicines

What do FAERS reports show for landiolol?

The FDA Adverse Event Reporting System holds 81 reports that list landiolol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 10 are coded as a death and 56 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

Drug Ineffective (a use or a product term, not a reaction)34
Off Label Use (a use or a product term, not a reaction)12
Bradycardia (named in the label)8
Ventricular Fibrillation7
Condition Aggravated (a use or a product term, not a reaction)6
Drug Ineffective For Unapproved Indication (a use or a product term, not a reaction)6
Atrial Fibrillation (a use or a product term, not a reaction)5
Cardiac Failure (named in the label)5

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Other beta blockers: the pharmacologic class, with prices and generics
Landiolol side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other